| [1] |
Amin MB, Greene FL, Edge SB, et al. The eighth edition AJCC cancer staging manual: continuing to build a bridge from a population-based to a more "personalized" approach to cancer staging[J]. CA Cancer J Clin, 2017, 67(2)：93-99.
|
| [2] |
Paik S, Shak S, Tang G, et al. A multigene assay to predict recurrence of tamoxifen-treated, node negative breast cancer[J]. N Engl J Med, 2004, 351(27)：2817-2826.
|
| [3] |
Kathy S, Albain W, Shak S, et al. Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial[J]. Lancet Oncol, 2010, 11(1)：55-65.
|
| [4] |
Paik S, Tang G, Shak S, et al. Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer[J]. J Clin Oncol, 2006, 24(23)：3726-3734.
|
| [5] |
Goldstein LJ, Gray R, Badve S, et al. Prognostic utility of the 21-gene assay in hormone receptor-positive operable breast cancer compared with classical clinicopathologic features[J]. J Clin Oncol, 2008, 26(25)：4063-4071.
|
| [6] |
Eleftherios P. Mamounas GT, Fisher B, et al. Association between the 21-gene recurrence score assay and risk of locoregional recurrence in node-negative, estrogen receptor-positive breast cancer-results from NSABP B-14 and NSABP B-20[J]. J Clin Oncol, 28(10)：1677-1683.
|
| [7] |
Dowsett M, Cuzick J, Wale C, et al. Prediction of risk of distant recurrence using the 21-gene recurrence score in node-negative and node-positive postmenopausal patients with breast cancer treated with anastrozole or tamoxifen: a TransATAC study[J]. J Clin Oncol, 2010, 28(11)：1829-1834.
|
| [8] |
Sparano JA, Gray RJ, Makower DF, et al. Prospective validation of a 21-gene expression assay in breast cancer[J]. N Engl J Med, 2015, 373(21)：2005-2014.
|
| [9] |
Sparano JA, Gray RJ, Makower DF, et al. Adjuvant chemotherapy guided by a 21-gene expression assay in breast cancer[J]. N Engl J Med, 2018, 379(2)：111-121.
|
| [10] |
Sparano JA, Gray RJ, Ravdin PM, et al. Clinical and genomic risk to guide the use of adjuvant therapy for breast cancer[J]. N Engl J Med, 2019, 380(25)：2395-2405.
|
| [11] |
Weiser R, Haque W, Polychronopoulou E, et al. The 21-gene recurrence score in node-positive, hormone receptor-positive, HER2-negative breast cancer: a cautionary tale from an NCDB analysis[J]. Breast Cancer Res Treat, 2021，185(3)：667-676.
|
| [12] |
Coates AS, Winer EP, Goldhirsch A, et al. Tailoring therapies--Improving the management of early breast cancer: St. Gallen international expert consensus on the primary therapy of early breast cancer[J]. Ann Oncol, 2015，26(8)：1533-1546.
|
| [13] |
Harris LN, Ismaila N, McShane LM, et al. Use of biomarkers to guide decisions on adjuvant systemic therapy for women with early-stage invasive breast cancer: American Society of Clinical Oncology clinical practice guideline[J]. J Clin Oncol, 2016, 34(10)：1134-1150.
|
| [14] |
Telli ML, Gradishar WJ, Ward JH. NCCN guidelines updates: breast cancer[J]. J Natl Compr Canc Netw, 2019, 17(5.5)：552-555.
|
| [15] |
Andre F, Ismaila N, Henry NL, et al. Use of biomarkers to guide decisions on adjuvant systemic therapy for women with early-stage invasive breast cancer: ASCO clinical practice guideline update-integration of results from TAILORx[J]. J Clin Oncol, 2019, 37(22)：1956-1964.
|
| [16] |
Slodkowska EA, Ross JS. MammaPrint 70-gene signature: another milestone in personalized medical care for breast cancer patients[J]. Expert Rev Mol Diagn, 2009, 9(5)：417-422.
|
| [17] |
van’t Veer LJ, Dai H, van de Vijver MJ, et al. Gene expression profiling predicts clinical outcome of breast cancer[J]. Nature, 2002, 415(6871)：530-536.
|
| [18] |
Bueno-de-Mesquita JM, van Harten WH, Retel VP, et al. Use of 70-gene signature to predict prognosis of patients with node-negative breast cancer: a prospective community-based feasibility study (RASTER)[J]. Lancet Oncol, 2007, 8(12)：1079-1087.
|
| [19] |
Mook S, Schmidt MK, Viale G, et al. The 70-gene prognosis-signature predicts disease outcome in breast cancer patients with 1－3 positive lymph nodes in an independent validation study[J]. Breast Cancer Res Treat, 2009, 116(2)：295-302.
|
| [20] |
Cardoso F, van’t Veer LJ, Bogaerts J, et al. 70-gene signature as an aid to treatment decisions in early-stage breast cancer[J]. N Engl J Med, 2016, 375(8)：717-729.
|
| [21] |
Caruana E, Foucher Y, Tessier P, et al. Patient-centered simulations to assess the usefulness of the 70-gene signature for adjuvant chemotherapy administration in early-stage breast cancer[J]. Breast Cancer Res Treat, 2019, 174(2)：537-542.
|
| [22] |
Tsai M, Lo S, Audeh W, et al. Association of 70-gene signature assay findings with physicians’ treatment guidance for patients with early breast cancer classified as intermediate risk by the 21-gene assay[J]. JAMA Oncol, 2018, 4(1): 133.
|
| [23] |
Goldhirsch A, Wood WC, Coates AS, et al. Strategies for subtypes--dealing with the diversity of breast cancer: highlights of the St. Gallen international expert consensus on the primary therapy of early breast cancer 2011[J]. Ann Oncol, 2011, 22(8)：1736-1747.
|
| [24] |
Krop I, Ismaila N, Andre F, et al. Use of biomarkers to guide decisions on adjuvant systemic therapy for women with early-stage invasive breast cancer: American Society of Clinical Oncology clinical practice guideline focused update[J]. J Clin Oncol, 2017, 35(24)：2838-2847.
|
| [25] |
Duffy MJ, Harbeck N, Nap M, et al. Clinical use of biomarkers in breast cancer: updated guidelines from the European Group on Tumor Markers (EGTM)[J]. Eur J Cancer, 2017, 75：284-298.
|
| [26] |
中国临床肿瘤学会指南工作委员会. 中国临床肿瘤学会乳腺癌诊疗指南(2019版)[M]. 北京：人民卫生出版社，2019：38-56.
|
| [27] |
Henry NL, Somerfield MR, Abramson VG, et al. Role of patient and disease factors in adjuvant systemic therapy decision making for early-stage, operable breast cancer: update of the ASCO endorsement of the Cancer Care Ontario Guideline[J]. J Clin Oncol, 2019，37(22)：1965-1977.
|
| [28] |
Parker JS, Mullins M, Cheang MC, et al. Supervised risk predictor of breast cancer based on intrinsic subtypes[J]. J Clin Oncol, 2009, 27(8)：1160-1167.
|
| [29] |
Wallden B, Storhoff J, Nielsen T, et al. Development and verification of the PAM50-based Prosigna breast cancer gene signature assay[J]. BMC Med Genomics, 2015, 8(1)：54.
|
| [30] |
Sestak I, Cuzick J, Dowsett M, et al. Prediction of late distant recurrence after 5 years of endocrine treatment: a combined analysis of patients from the Austrian breast and colorectal cancer study group 8 and arimidex, tamoxifen alone or in combination randomized trials using the PAM50 risk of recurrence score[J]. J Clin Oncol, 2015，33(8)：916-922.
|
| [31] |
Lænkholm AV, Jensen MB, Eriksen JO, et al. PAM50 risk of recurrence score predicts 10-year distant recurrence in a comprehensive Danish cohort of postmenopausal women allocated to 5 years of endocrine therapy for hormone receptor-positive early breast cancer[J]. J Clin Oncol, 2018, 36(8): 735-740.
|
| [32] |
Liu S, Chapman JA, Burnell MJ, et al. Prognostic and predictive investigation of PAM50 intrinsic subtypes in the NCIC CTG MA.21 phase III chemotherapy trial[J]. Breast Cancer Res Treat，2015，149(2): 439-448.
|
| [33] |
Gnant M, Filipits M, Greil R, et al. Predicting distant recurrence in receptor-positive breast cancer patients with limited clinicopathological risk: using the PAM50 risk of recurrence score in 1478 postmenopausal patients of the ABCSG-8 trial treated with adjuvant endocrine therapy alone[J]. Ann Oncol, 2014, 25(2)：339-345.
|
| [34] |
Gnant M, Sestak I, Filipits M, et al. Identifying clinically relevant prognostic subgroups of postmenopausal women with node-positive hormone receptor-positive early-stage breast cancer treated with endocrine therapy: a combined analysis of ABCSG-8 and ATAC using the PAM50 risk of recurrence score and intrinsic subtype[J]. Ann Oncol, 2015，26(8)：1685-1691.
|
| [35] |
Dowsett M, Sestak I, Lopez-Knowles E, et al. Comparison of PAM50 risk of recurrence score with Oncotype DX and IHC4 for predicting risk of distant recurrence after endocrine therapy[J]. J Clin Oncol, 2013, 31(22)：2783-2790.
|
| [36] |
Filipits M, Rudas M, Jakesz R, et al. A new molecular predictor of distant recurrence in ER-positive, HER2-negative breast cancer adds independent information to conventional clinical risk factors[J]. Clin Cancer Res, 2011, 17(18)：6012-6020.
|
| [37] |
Dubsky P, Brase JC, Jakesz R, et al. The EndoPredict score provides prognostic information on late distant metastases in ER+/HER2- breast cancer patients[J]. Br J Cancer, 2013, 109(12)：2959-2964.
|
| [38] |
Filipits M, Rudas M, Jakesz R, et al. A new molecular predictor of distant recurrence in ER-positive, HER2-negative breast cancer adds independent information to conventional clinical risk factors[J]. Clin Cancer Res, 2011, 17(18): 6012-6020.
|
| [39] |
Filipits M, Dubsky P, Rudas M, et al. Prediction of distant recurrence using EndoPredict among women with ER+，HER2- node-positive and node-negative breast cancer treated with endocrine therapy only[J]. Clin Cancer Res, 2019, 25(13)：3865-3872.
|
| [40] |
Sestak I, Martin M, Dubsky P, et al. Prediction of chemotherapy benefit by EndoPredict in patients with breast cancer who received adjuvant endocrine therapy plus chemotherapy or endocrine therapy alone[J]. Breast Cancer Res Treat, 2019, 176(2)：377-386.
|
| [41] |
Loibl S, Weber K, Huober J, et al. Risk assessment after neoadjuvant chemotherapy in Luminal breast cancer using a clinicomolecular predictor[J]. Clin Cancer Res, 2018, 24(14)：3358-3365.
|
| [42] |
Buus R, Sestak I, Kronenwett R, et al. Comparison of EndoPredict and EPclin with Oncotype DX recurrence score for prediction of risk of distant recurrence after endocrine therapy[J]. J Natl Cancer Inst, 2016, 108(11)：149.
|
| [43] |
Sestak I, Buus R, Cuzick J, et al. Comparison of the performance of 6 prognostic signatures for estrogen receptor-positive breast cancer: a secondary analysis of a randomized clinical trial[J]. JAMA Oncol，2018，4(4)：545-553.
|
| [44] |
Burstein HJ, Curigliano G, Loibl S, et al. Estimating the benefits of therapy for early-stage breast cancer: the St. Gallen international consensus guidelines for the primary therapy of early breast cancer[J]. Ann Oncol, 2019, 30(10)：1541-1557.
|
| [45] |
Cardoso F, Kyriakides S, Ohno S, et al. Early breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up[J]. Ann Oncol, 2019, 30(8)：1194-1220.
|
| [46] |
Ma XJ, Salunga R, Dahiya S, et al. A five-gene molecular grade index and HOXB13：IL17BR are complementary prognostic factors in early stage breast cancer[J]. Clin Cancer Res, 2008, 14(9)：2601-2608.
|
| [47] |
Sgroi DC, Sestak I, Cuzick J, et al. Prediction of late distant recurrence in patients with oestrogen-receptor-positive breast cancer: a prospective comparison of the breast-cancer index (BCI) assay, 21-gene recurrence score, and IHC4 in the TransATAC study population[J]. Lancet Oncol, 2013, 14(11): 1067-1076.
|
| [48] |
Habel LA, Sakoda LC, Achacoso N, et al. HOXB13：IL17BR and molecular grade index and risk of breast cancer death among patients with lymph node-negative invasive disease[J]. Breast Cancer Res, 2013, 15(2)：R24.
|
| [49] |
Zhang Y, Schnabel CA, Schroeder BE, et al. Breast cancer index identifies early-stage estrogen receptor-positive breast cancer patients at risk for early- and late-distant recurrence[J]. Clin Cancer Res, 2013, 19(15)：4196-4205.
|
| [50] |
Zhang Y, Schroeder BE, Jerevall PL, et al. A novel breast cancer index for prediction of distant recurrence in HR+ early-stage breast cancer with one to three positive nodes[J]. Clin Cancer Res, 2017, 23(23)：7217-7224.
|
| [51] |
Sgroi DC, Chapman JA, Badovinac-Crnjevic T, et al. Assessment of the prognostic and predictive utility of the Breast Cancer Index (BCI): an NCIC CTG MA.14 study[J]. Breast Cancer Res, 2016, 18(1)：1.
|
| [52] |
Bartlett JMS, Sgroi DC, Treuner K, et al. Breast Cancer Index and prediction of benefit from extended endocrine therapy in breast cancer patients treated in the adjuvant tamoxifen - to offer more? (aTTom) trial[J]. Ann Oncol, 2019，30(11)：1776-1783.
|
| [53] |
Jerevall PL, Brock J, Palazzo J, et al. Discrepancy in risk assessment of hormone receptor positive early-stage breast cancer patients using breast cancer index and recurrence score[J]. Breast Cancer Res Treat, 2019，173(2)：375-383.
|
| [54] |
Varga Z, Sinn P, Seidman AD. Summary of head-to-head comparisons of patient risk classifications by the 21-gene Recurrence Score (RS) assay and other genomic assays for early breast cancer.[J] Int J Cancer, 2019, 145(4)：882-893.
|
| [55] |
Zhang G, Wang Y, Chen B, et al. Characterization of frequently mutated cancer genes in Chinese breast tumors: a comparison of Chinese and TCGA cohorts[J]. Ann Transl Med, 2019, 7(8)：179.
|
| [56] |
Yap YS, Lu YS, Tamura K, et al. Insights into breast cancer in the East vs the West[J]. JAMA Oncol, 2019, 5(10)：1489-1496.
|